Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DapaBalci-Leap
NCT05884866Phase 2Completed
- Sponsor
- Klinikum Nürnberg
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of balcinrenone and dapagliflozin in chronic kidney disease (CKD) (4 arms), sponsored by Klinikum Nürnberg. Primary endpoint: 24-hour renal glucose excretion at 28 days. Started Jul 2023; status: completed.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05884866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05884866.